


PHARMACEUTICAL 2017

Qualigen Therapeutics Inc. Rank 294 of 313







PHARMACEUTICAL 2017

Qualigen Therapeutics Inc. Rank 294 of 313



The relative strengths and weaknesses of Qualigen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Qualigen Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Qualigen Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 747% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,352%, being 936% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	7,203
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,134
Liabilities, Non-Current	0
Other Assets	10
Other Compr. Net Income	0
Other Expenses	273
Other Liabilities	0
Other Net Income	62
Property and Equipment	24
Research and Development	13,292
Revenues	0
Selling, General and Administrative Expense	4,882

Output Variable	Value in 1000 USD
Assets	7,237
Liabilities	3,134
Expenses	18,447
Stockholders Equity	4,103
Net Income	-18,385
Comprehensive Net Income	-18,385
Economic Capital Ratio	-1,352%